期刊
JOURNAL OF HEPATOLOGY
卷 68, 期 6, 页码 1272-1285出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2018.01.030
关键词
Mesenchymal stromal cell; Liver disease; Enrichment; Priming; Genetic engineering
资金
- Saudi Arabian Cultural Bureau
- National Institute of Health Research (NIHR) Birmingham Liver Biomedical Research Unit (BRU)
- Korea Health Industry Development Institute (KHIDI) - Ministry of Health AMP
- Welfare, Republic of Korea [HI15C2364, HI17C1365]
- Basic Science Research Program
- National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2017R1D1A1A02019212, NRF-2017R1A5A2015369]
The therapeutic potential of mesenchymal stromal cells (MSCs) in the treatment of liver fibrosis is predominantly based on their immunosuppressive properties, and their ability to secrete various trophic factors. This potential has been investigated in clinical and preclinical studies. Although the therapeutic mechanisms of MSC transplantation are still not fully characterised, accumulating evidence has revealed that various trophic factors secreted by MSCs play key therapeutic roles in regeneration by alleviating inflammation, apoptosis, and fibrosis as well as stimulating angiogenesis and tissue regeneration in damaged liver. In this review, we summarise the safety, efficacy, potential transplantation routes and therapeutic effects of MSCs in patients with liver fibrosis. We also discuss some of the key strategies to enhance the functionality of MSCs, which include sorting and/or priming with factors such as cytokines, as well as genetic engineering. (C) 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据